V-Block封堵支架与硬化剂装置治疗静脉曲张的回顾性分析
本研究回顾性分析51例有症状的大隐静脉反流患者,在门诊采用新型非肿胀麻醉、非热消融技术,即V-Block封堵支架联合硬化剂治疗。术后7天完全闭塞率达98%,无器械移位或深静脉血栓等并发症,生活质量和疼痛评分显著改善,3年随访闭塞率为77.8%。
要点
- V-Block支架联合硬化剂治疗大隐静脉反流,7天完全闭塞率达98%。
- 无器械移位、部署部位损伤或深静脉血栓等并发症记录。
- 3年随访闭塞率为77.8%,生活质量和疼痛评分显著改善。
核心结论
- V-Block封堵支架联合硬化剂治疗大隐静脉反流具有良好的安全性和性能,达到静脉闭塞的主要终点。
研究设计与样本
- 回顾性分析,纳入51例有症状且记录有大隐静脉反流的患者,在门诊环境下接受V-Block封堵装置治疗。
- 术后1周、1个月和3个月进行随访,采用双功能超声评估大隐静脉闭塞,并使用Aberdeen静脉曲张问卷和静脉严重程度评分评估生活质量变化。
主要发现
- 术后7天随访时,98%的患者实现大隐静脉完全闭塞。
- 未观察到部署部位损伤或V-Block装置移位。
- 未记录到深静脉血栓或其他并发症;51次手术中1例患者出现浅静脉炎不良事件,经保守治疗4天内消退且无残留影响。
- Aberdeen静脉生活质量测量和疼痛评分显著改善。
- 3年后18例患者愿意接受双功能超声随访,闭塞率为77.8%,此期间无器械相关并发症。
临床怎么用
- V-Block封堵支架可在门诊环境下无需肿胀麻醉使用,作为大隐静脉反流的微创治疗选择。
- 装置部署后可联合超声引导下硬化治疗,设计用于降低血栓和硬化剂向深静脉及肺循环栓塞的风险。
局限性
- 本研究为回顾性分析,3年随访仅18例患者愿意接受超声检查,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The procedure aims to show our results with a novel nontumescent, nonthermal technique to treat varicose veins. The V-block occlusion stent is a minimally invasive device for treating reflux of the great saphenous vein (GSV). It is an office-based procedure that does not require tumescence anesthesia. The V-block stent is a self-expandable device that functions as a vein occluder and blood clot trap. Once the V-block is in place, further treatment of the saphenous vein such as ultrasound-guided sclerotherapy can be performed. The V-block device is intended to eliminate the possibility of forwarding passage of clot and sclerosant (embolization) to the deep and pulmonary circulations. METHODS: Patients were treated in an outpatient setting with the V-block occluding device. Follow-up was performed using duplex ultrasound to assess occlusion of the saphenous vein as well as the Aberdeen Varicose Vein Questionnaire and Venous Severity Scoring to determine changes in quality of life after the procedure. Patients were followed up at 1 week, 1 month, and 3 months after V-block placement. Duplex scanning was performed to confirm GSV occlusion at all follow-up visits. After deployment of the occlusion stent, a maximum of 2% polidocanol foam was injected with a double barrel syringe which simultaneously evacuated blood from the greater saphenous vein. Follow-up assessment for safety included evaluation of potential complications, device migration, and potential injury at the deployment site. RESULTS: Fifty-one symptomatic subjects with documented GSV reflux were enrolled in the study. Complete occlusion of the GSV was achieved in 98% of the patients during the 7-day postprocedural visit. There was no injury at the deployment site. No migration of the V-block device was observed. No deep vein thrombosis or any other complication was recorded. One patient of the 50 patients and 51 procedures experienced an adverse event, phlebitis that resolved under conservative therapy within 4 days with no residual effect. There was a significant improvement in the Aberdeen Vein quality of life measurements and the pain scores. After 3 years, 18 patients were willing to undergo a duplex follow-up examination. The occlusion rate after 3 years was 77.8. There were no device-related complications after this period. CONCLUSIONS: The study demonstrated a good safety and performance profile without any major adverse events. The primary end point of vein occlusion and obliteration was met.
引用
- Kolvenbach RR, Elias S, Belinky A, et al. The V-Block Occlusion Stent and Sclerotherapy Device for Varicose Vein Treatment: A Retrospective Analysis. Ann Vasc Surg. 2019. PMID: 31009711. doi:10.1016/j.avsg.2019.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。